3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
8
Glioma
4
Multiple Myeloma
3
Thyroid Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Glioblastoma
2
Colorectal Neoplasms
2
Astrocytoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Sarcoma
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurocytoma
1
Neuroblastoma
1
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
1
Interventions
Rituximab
5
Specimen Handling
3
Biopsy
3
ibrutinib
2
binimetinib
2
Vemurafenib
2
Cyclophosphamide
2
Cladribine
2
venetoclax
1
tovorafenib
1
polatuzumab vedotin
1
pembrolizumab
1
obinutuzumab
1
immunotoxin HA22
1
fludarabine phosphate
1
fludarabine
1
encorafenib
1
acalabrutinib
1
Whole-Body Irradiation
1
Transplantation
1
Tacrolimus
1
Spinal Puncture
1
Radiotherapy
1
Prednisone
1
Peripheral Blood Stem Cell Transplantation
1
Mycophenolic Acid
1
Magnetic Resonance Spectroscopy
1
Lenalidomide
1
High-Energy Shock Waves
1
Famotidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Leukemia, Hairy Cell
×
dabrafenib
×
90 days
×
Clear all
No trials found.